For decades, testosterone was assumed to fuel prostate cancer — a belief rooted in Charles Huggins' 1941 Nobel Prize-winning work showing that castration caused prostate cancer regression. The logical inference: if removing testosterone shrinks prostate cancer, adding testosterone must grow it. This inference dominated urology for 60 years. Modern evidence tells a fundamentally different story.
The Saturation Model
Abraham Morgentaler's saturation model, now supported by substantial clinical data, proposes that the prostate's response to testosterone is saturable. Below a saturation threshold (~250–300 ng/dL), increasing testosterone does increase prostate growth. Above that threshold, additional testosterone has minimal prostate effect because androgen receptors are already fully occupied.
Since TRT brings testosterone from hypogonadal levels to the normal range (typically 500–800 ng/dL) — well above the saturation threshold — it should not significantly stimulate prostate growth. This model is consistent with the clinical observation that TRT does not dramatically increase PSA in most men.
Large-Scale Evidence
The TRAVERSE trial — enrolling 5,246 men ages 45–80 with cardiovascular risk factors — found no significant difference in prostate cancer incidence between the testosterone and placebo groups over a median 33-month follow-up. Multiple meta-analyses of smaller studies have reached similar conclusions: TRT does not increase prostate cancer risk above baseline.
What TRT Does to PSA
TRT typically produces a modest PSA increase — 0.3–0.5 ng/mL on average — during the first 6–12 months. This reflects increased prostate cellular activity under restored testosterone, not cancer. PSA stabilizes after this initial rise. A sustained, progressive PSA increase beyond the initial adjustment warrants investigation — but the initial bump is expected and not alarming.
Prostate Monitoring on TRT
- Baseline: PSA and digital rectal exam before starting TRT
- 6 months: Repeat PSA. Expect 0.3–0.5 increase — this is normal.
- Annual: PSA monitoring. Follow age-appropriate screening guidelines.
- Red flags: PSA >4.0, PSA velocity >0.75/year, or suspicious DRE findings warrant urology referral regardless of TRT status
The Bottom Line
The Fear Is Outdated
Modern evidence does not support the historical belief that TRT causes or accelerates prostate cancer. The saturation model and large-scale trial data consistently show that physiological testosterone replacement does not increase prostate cancer risk above baseline. Standard prostate screening (PSA and DRE) should continue on TRT — not because TRT increases risk, but because age-appropriate screening is good medicine regardless.